The peroxisome proliferator-activated receptors in cardiovascular diseases: Experimental benefits and clinical challenges

British Journal of Pharmacology

Volumn 172, Issue 23, 2015, Pages 5512-5522

  Cheang, Wai San ^a   Tian, Xiao Yu ^b   Wong, Wing Tak ^b   Huang, Yu ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BEZAFIBRATE; CHINESE DRUG; CIPROFIBRATE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; INDEGLITAZAR; NETOGLITAZONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; ROSIGLITAZONE; SIPOGLITAZAR; TROGLITAZONE; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; ANTIOXIDANT; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; DIABETES MELLITUS; DIABETIC RETINOPATHY; DRUG SURVEILLANCE PROGRAM; EXPERIMENTAL STUDY; GLUCOSE METABOLISM; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; LIPID METABOLISM; META ANALYSIS (TOPIC); METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PHYSIOLOGICAL PROCESS; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN FUNCTION; REVIEW; TRANSCRIPTION REGULATION; VASCULAR DISEASE; AGONISTS; ANIMAL; CARDIOVASCULAR DISEASES; METABOLISM;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIOXIDANTS; CARDIOVASCULAR DISEASES; HUMANS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS;

EID: 84949531083     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13029     Document Type: Review

References (97)

1. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: Nuclear Hormone Receptors. Br J Pharmacol 170: 1652-1675.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013b). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol 170: 1797-1867.
3. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013c). The Concise Guide to PHARMACOLOGY 2013/14: G Protein-Coupled Receptors. Br J Pharmacol 170: 1459-1581.
4. Asztalos BF, Collins D, Horvath KV, Bloomfield HE, Robins SJ, Schaefer EJ, (2008). Relation of gemfibrozil treatment and high-density lipoprotein subpopulation profile with cardiovascular events in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Metabolism 57: 77-83.
5. Atanasov AG, Wang JN, Gu SP, Bu J, Kramer MP, Baumgartner L, et al. (2013). Honokiol: a non-adipogenic PPARγ agonist from nature. Biochim Biophys Acta 1830: 4813-4819.
6. Babaev VR, Ishiguro H, Ding L, Yancey PG, Dove DE, Kovacs WJ, et al. (2007). Macrophage expression of peroxisome proliferator-activated receptor-alpha reduces atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 116: 1404-1412.
7. Barish GD, Atkins AR, Downes M, Olson P, Chong LW, Nelson M, et al. (2008). PPARdelta regulates multiple proinflammatory pathways to suppress atherosclerosis. Proc Natl Acad Sci U S A 105: 4271-4276.
8. Biscetti F, Straface G, Arena V, Stigliano E, Pecorini G, Rizzo P, et al. (2009). Pioglitazone enhances collateral blood flow in ischemic hindlimb of diabetic mice through an Akt-dependent VEGF-mediated mechanism, regardless of PPARgamma stimulation. Cardiovasc Diabetol 8: 49.
9. Bojic LA, Burke AC, Chhoker SS, Telford DE, Sutherland BG, Edwards JY, et al. (2014). Peroxisome proliferator-activated receptor delta agonist GW1516 attenuates diet-induced aortic inflammation, insulin resistance, and atherosclerosis in low-density lipoprotein receptor knockout mice. Arterioscler Thromb Vasc Biol 34: 52-60.
10. Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W, (1996). Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 137: 354-366.
11. Calkin AC, Allen TJ, Lassila M, Tikellis C, Jandeleit-Dahm KA, Thomas MC, (2007). Increased atherosclerosis following treatment with a dual PPAR agonist in the ApoE knockout mouse. Atherosclerosis 195: 17-22.
12. Campia U, Matuskey LA, Panza JA, (2006). Peroxisome proliferator-activated receptor-gamma activation with pioglitazone improves endothelium-dependent dilation in nondiabetic patients with major cardiovascular risk factors. Circulation 113: 867-875.
13. Cariou B, Zaïr Y, Staels B, Bruckert E, (2011). Effects of the new dual PPAR alpha/delta agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism. Diabetes Care 34: 2008-2014.
14. Chakrabarti R, Vikramadithyan RK, Misra P, Hiriyan J, Raichur S, Damarla RK, et al. (2003). Ragaglitazar: a novel PPAR alpha PPAR gamma agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models. Br J Pharmacol 140: 527-537.
15. Chang L, Villacorta L, Zhang J, Garcia-Barrio MT, Yang K, Hamblin M, et al. (2009). Vascular smooth muscle cell-selective peroxisome proliferator-activated receptor-deletion leads to hypotension. Circulation 119: 2161-2169.
16. Chang L, Villacorta L, Li R, Hamblin M, Xu W, Dou C, et al. (2012). Loss of perivascular adipose tissue on peroxisome proliferator-activated receptor-γ deletion in smooth muscle cells impairs intravascular thermoregulation and enhances atherosclerosis. Circulation 126: 1067-1078.
17. Cheang WS, Tian XY, Wong WT, Lau CW, Lee SS, Chen ZY, et al. (2014). Metformin protects endothelial function in diet-induced obese mice by inhibition of endoplasmic reticulum stress through 5′ adenosine monophosphate-activated protein kinase-peroxisome proliferator-activated receptor δ pathway. Arterioscler Thromb Vasc Biol 34: 830-836.
18. Chen KC, Chen CY, (2014). In silico identification of potent PPAR-γ agonists from traditional Chinese medicine: a bioactivity prediction, virtual screening, and molecular dynamics study. Evid Based Complement Alternat Med 2014: 192452.
19. Chen KC, Chang SS, Huang HJ, Lin TL, Wu YJ, Chen CY, (2012). Three-in-one agonists for PPAR-α, PPAR-γ, and PPAR-δ from traditional Chinese medicine. J Biomol Struct Dyn 30: 662-683.
20. Chen Y, Hu Y, Lin M, Jenkins AJ, Keech AC, Mott R, et al. (2013). Therapeutic effects of PPARα agonists on diabetic retinopathy in type 1 diabetes models. Diabetes 62: 261-272.
21. Chen Z, Ishibashi S, Perrey S, Osuga J, Gotoda T, Kitamine T, et al. (2001). Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL. Arterioscler Thromb Vasc Biol 21: 372-377.
22. Cho DH, Choi YJ, Jo SA, Jo I, (2004). Nitric oxide production and regulation of endothelial nitric-oxide synthase phosphorylation by prolonged treatment with troglitazone: evidence for involvement of peroxisome proliferator-activated receptor (PPAR) gamma-dependent and PPARgamma-independent signaling pathways. J Biol Chem 279: 2499-2506.
23. Choi JH, Banks AS, Kamenecka TM, Busby SA, Chalmers MJ, Kumar N, et al. (2011). Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation. Nature 477: 477-481.
24. Choi YJ, Roberts BK, Wang X, Geaney JC, Naim S, Wojnoonski K, et al. (2012). Effects of the PPAR-δ agonist MBX-8025 on atherogenic dyslipidemia. Atherosclerosis 220: 470-476.
25. Chu K, Lee ST, Koo JS, Jung KH, Kim EH, Sinn DI, et al. (2006). Peroxisome proliferator-activated receptor-gamma-agonist, rosiglitazone, promotes angiogenesis after focal cerebral ischemia. Brain Res 1093: 208-218.
26. Claudel T, Leibowitz MD, Fievet C, Tailleux A, Wagner B, Repa JJ, et al. (2001). Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor. Proc Natl Acad Sci U S A 98: 2610-2615.
27. Delerive P, De Bosscher K, Besnard S, Vanden Berghe W, Peters JM, Gonzalez FJ, et al. (1999). Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem 274: 32048-32054.
28. Delerive P, Gervois P, Fruchart JC, Staels B, (2000). Induction of IkappaBalpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators. J Biol Chem 275: 36703-36707.
29. DiRenzo J, Soderstrom M, Kurokawa R, Ogliastro MH, Ricote M, Ingrey S, et al. (1997). Peroxisome proliferator-activated receptors and retinoic acid receptors differentially control the interactions of retinoid X receptor heterodimers with ligands, coactivators, and corepressors. Mol Cell Biol 17: 2166-2176.
30. Duez H, Chao YS, Hernandez M, Torpier G, Poulain P, Mundt S, et al. (2002). Reduction of atherosclerosis by the peroxisome proliferator-activated receptor alpha agonist fenofibrate in mice. J Biol Chem 277: 48051-48057.
31. Fievet C, Fruchart JC, Staels B, (2006). PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome. Curr Opin Pharmacol 6: 606-614.
32. Forman BM, Chen J, Evans RM, (1997). Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci U S A 94: 4312-4317.
33. Fruchart JC, Brewer B, Leitersdorf E, Brochier M, Brown G, Calvo C, et al. (1998). Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Am J Cardiol 81: 912-917.
34. Gearing KL, Gottlicher M, Teboul M, Widmark E, Gustafsson JA, (1993). Interaction of the peroxisome-proliferator-activated receptor and retinoid X receptor. Proc Natl Acad Sci U S A 90: 1440-1444.
35. Giles TD, Sander GE, (2007). Effects of thiazolidinediones on blood pressure. Curr Hypertens Rep 9: 332-337.
36. Glineur C, Gross B, Neve B, Rommens C, Chew GT, Martin-Nizard F, et al. (2013). Fenofibrate inhibits endothelin-1 expression by peroxisome proliferator-activated receptor alpha-dependent and independent mechanisms in human endothelial cells. Arterioscler Thromb Vasc Biol 33: 621-628.
37. Gonzalez FJ, Shah YM, (2008). PPARalpha: mechanism of species differences and hepatocarcinogenesis of peroxisome proliferators. Toxicology 246: 2-8.
38. Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, Ali F, Sholley C, Worrall C, et al. (2010). Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 304: 411-418.
39. Group AS, Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, et al. (2010). Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 362: 1563-1574.
40. Gupta RA, Wang D, Katkuri S, Wang H, Dey SK, DuBois RN, (2004). Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-delta accelerates intestinal adenoma growth. Nat Med 10: 245-247.
41. Halabi CM, Beyer AM, De Lange WJ, Keen HL, Baumbach GL, Faraci FM, et al. (2008). Interference with PPAR gamma function in smooth muscle causes vascular dysfunction and hypertension. Cell Metab 7: 215-226.
42. Hu Q, Zhang XJ, Liu CX, Wang XP, Zhang Y, (2010). PPARgamma1-induced caveolin-1 enhances cholesterol efflux and attenuates atherosclerosis in apolipoprotein E-deficient mice. J Vasc Res 47: 69-79.
43. Huang PH, Sata M, Nishimatsu H, Sumi M, Hirata Y, Nagai R, (2008). Pioglitazone ameliorates endothelial dysfunction and restores ischemia-induced angiogenesis in diabetic mice. Biomed Pharmacother 62: 46-52.
44. Jiang C, Ting AT, Seed B, (1998). PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391: 82-86.
45. Jimenez R, Sanchez M, Zarzuelo MJ, Romero M, Quintela AM, Lopez-Sepulveda R, et al. (2010). Endothelium-dependent vasodilator effects of peroxisome proliferator-activated receptor beta agonists via the phosphatidyl-inositol-3 kinase-Akt pathway. J Pharmacol Exp Ther 332: 554-561.
46. Kanda T, Brown JD, Orasanu G, Vogel S, Gonzalez FJ, Sartoretto J, et al. (2009). PPARgamma in the endothelium regulates metabolic responses to high-fat diet in mice. J Clin Invest 119: 110-124.
47. Kliewer SA, Umesono K, Mangelsdorf DJ, Evans RM, (1992). Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin D3 signalling. Nature 355: 446-449.
48. Kliewer SA, Sundseth SS, Jones SA, Brown PJ, Wisely GB, Koble CS, et al. (1997). Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci U S A 94: 4318-4323.
49. Kohlroser J, Mathai J, Reichheld J, Banner BF, Bonkovsky HL, (2000). Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration. Am J Gastroenterol 95: 272-276.
50. Lee CH, Chawla A, Urbiztondo N, Liao D, Boisvert WA, Evans RM, (2003). Transcriptional repression of atherogenic inflammation: modulation by PPAR delta. Science 302: 453-457.
51. Lee CH, Olson P, Hevener A, Mehl I, Chong LW, Olefsky JM, et al. (2006a). PPARdelta regulates glucose metabolism and insulin sensitivity. Proc Natl Acad Sci U S A 103: 3444-3449.
52. Lee KS, Park JH, Lee S, Lim HJ, Jang Y, Park HY, (2006b). Troglitazone inhibits endothelial cell proliferation through suppression of casein kinase 2 activity. Biochem Biophys Res Commun 346: 83-88.
53. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE, (2007). Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 298: 1180-1188.
54. Lincoff AM, Tardif JC, Neal B, Nicholls SJ, Ryden L, Schwartz GG, et al. (2013). Evaluation of the dual peroxisome proliferator-activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: rationale and design of the AleCardio trial. Am Heart J 166: 429-434.
55. Liu Y, Tian XY, Mao G, Fang X, Fung ML, Shyy JY, et al. (2012). Peroxisome proliferator-activated receptor-γ ameliorates pulmonary arterial hypertension by inhibiting 5-hydroxytryptamine 2B receptor. Hypertension 60: 1471-1478.
56. Mahaffey KW, Hafley G, Dickerson S, Burns S, Tourt-Uhlig S, White J, et al. (2013). Results of a reevaluation of cardiovascular outcomes in the RECORD trial. Am Heart J 166: 240-249.e1.
57. Marchesi C, Rehman A, Rautureau Y, Kasal DA, Briet M, Leibowitz A, et al. (2012). Protective role of vascular smooth muscle cell PPAR in angiotensin II-induced vascular disease. Cardiovasc Res 97: 562-570.
58. Marder W, Khalatbari S, Myles JD, Hench R, Lustig S, Yalavarthi S, et al. (2013). The peroxisome proliferator activated receptor-γ pioglitazone improves vascular function and decreases disease activity in patients with rheumatoid arthritis. J Am Heart Assoc 2: e000441.
59. Meier CA, Chicheportiche R, Juge-Aubry CE, Dreyer MG, Dayer JM, (2002). Regulation of the interleukin-1 receptor antagonist in THP-1 cells by ligands of the peroxisome proliferator-activated receptor gamma. Cytokine 18: 320-328.
60. Mittra S, Sangle G, Tandon R, Sharma S, Roy S, Khanna V, et al. (2007). Increase in weight induced by muraglitazar, a dual PPARalpha/gamma agonist, in db/db mice: adipogenesis/or oedema? Br J Pharmacol 150: 480-487.
61. Neve BP, Corseaux D, Chinetti G, Zawadzki C, Fruchart JC, Duriez P, et al. (2001). PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages. Circulation 103: 207-212.
62. Nissen SE, Wolski K, (2007). Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356: 2457-2471.
63. Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kupfer S, Perez A, et al. (2008). Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 299: 1561-1573.
64. Okura T, Nakamura M, Takata Y, Watanabe S, Kitami Y, Hiwada K, (2000). Troglitazone induces apoptosis via the p53 and Gadd45 pathway in vascular smooth muscle cells. Eur J Pharmacol 407: 227-235.
65. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledge base of drug targets and their ligands. Nucl. Acids Res. 42 (Database Issue): D1098-1106.
66. Pelham CJ, Ketsawatsomkron P, Groh S, Grobe JL, de Lange WJ, Ibeawuchi SR, et al. (2012). Cullin-3 regulates vascular smooth muscle function and arterial blood pressure via PPARγ and RhoA/Rho-kinase. Cell Metab 16: 462-472.
67. Perrone CE, Shao L, Williams GM, (1998). Effect of rodent hepatocarcinogenic peroxisome proliferators on fatty acyl-CoA oxidase, DNA synthesis, and apoptosis in cultured human and rat hepatocytes. Toxicol Appl Pharmacol 150: 277-286.
68. Plutzky J, (2011). The PPAR-RXR transcriptional complex in the vasculature: energy in the balance. Circ Res 108: 1002-1016.
69. Pollock CB, Rodriguez O, Martin PL, Albanese C, Li X, Kopelovich L, et al. (2010). Induction of metastatic gastric cancer by peroxisome proliferator-activated receptorδ activation. PPAR Res 2010: 571783.
70. Quintela AM, Jimenez R, Gomez-Guzman M, Zarzuelo MJ, Galindo P, Sanchez M, et al. (2012). Activation of peroxisome proliferator-activated receptor-β/-δ (PPARβ/δ) prevents endothelial dysfunction in type 1 diabetic rats. Free Radic Biol Med 53: 730-741.
71. Remick J, Weintraub H, Setton R, Offenbacher J, Fisher E, Schwartzbard A, (2008). Fibrate therapy: an update. Cardiol Rev 16: 129-141.
72. Rosen ED, Spiegelman BM, (2001). PPARgamma: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 276: 37731-37734.
73. Scatena R, Bottoni P, Vincenzoni F, Messana I, Martorana GE, Nocca G, et al. (2003). Bezafibrate induces a mitochondrial derangement in human cell lines: a PPAR-independent mechanism for a peroxisome proliferator. Chem Res Toxicol 16: 1440-1447.
74. Scott R, O'Brien R, Fulcher G, Pardy C, d'Emden M, Tse D, et al. (2009). Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care 32: 493-498.
75. Srivastava RA, Jahagirdar R, Azhar S, Sharma S, Bisgaier CL, (2006). Peroxisome proliferator-activated receptor-alpha selective ligand reduces adiposity, improves insulin sensitivity and inhibits atherosclerosis in LDL receptor-deficient mice. Mol Cell Biochem 285: 35-50.
76. Tenenbaum A, Motro M, Fisman EZ, Schwammenthal E, Adler Y, Goldenberg I, et al. (2004). Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation 109: 2197-2202.
77. Tenenbaum A, Motro M, Fisman EZ, Adler Y, Shemesh J, Tanne D, et al. (2005a). Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients. Eur Heart J 26: 2032-2038.
78. Tenenbaum A, Motro M, Fisman EZ, Tanne D, Boyko V, Behar S, (2005b). Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med 165: 1154-1160.
79. Tenkanen L, Manttari M, Kovanen PT, Virkkunen H, Manninen V, (2006). Gemfibrozil in the treatment of dyslipidemia: an 18-year mortality follow-up of the Helsinki Heart Study. Arch Intern Med 166: 743-748.
80. Tian J, Wong WT, Tian XY, Zhang P, Huang Y, Wang N, (2010). Rosiglitazone attenuates endothelin-1-induced vasoconstriction by upregulating endothelial expression of endothelin B receptor. Hypertension 56: 129-135.
81. Tian XY, Wong WT, Wang NP, Lu Y, Cheang WS, Liu J, et al. (2012). PPARδ activation protects endothelial function in diabetic mice. Diabetes 61: 3285-3293.
82. Tordjman KM, Semenkovich CF, Coleman T, Yudovich R, Bak S, Osher E, et al. (2007). Absence of peroxisome proliferator-activated receptor-alpha abolishes hypertension and attenuates atherosclerosis in the Tsukuba hypertensive mouse. Hypertension 50: 945-951.
83. Tousoulis D, Andreou I, Antoniades C, Tentolouris C, Stefanadis C, (2008). Role of inflammation and oxidative stress in endothelial progenitor cell function and mobilization: therapeutic implications for cardiovascular diseases. Atherosclerosis 201: 236-247.
84. Vallarino C, Perez A, Fusco G, Liang H, Bron M, Manne S, et al. (2013). Comparing pioglitazone to insulin with respect to cancer, cardiovascular and bone fracture endpoints, using propensity score weights. Clin Drug Investig 33: 621-631.
85. Wang G, He L, Liu J, Yu J, Feng X, Li F, et al. (2013). Coronary flow velocity reserve is improved by PPAR-α agonist fenofibrate in patients with hypertriglyceridemia. Cardiovasc Ther 31: 161-167.
86. Wang YX, Lee CH, Tiep S, Yu RT, Ham J, Kang H, et al. (2003). Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity. Cell 113: 159-170.
87. Wilcox R, Kupfer S, Erdmann E, (2008). Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10). Am Heart J 155: 712-717.
88. Woldt E, Terrand J, Mlih M, Matz RL, Bruban V, Coudane F, et al. (2012). The nuclear hormone receptor PPARγ counteracts vascular calcification by inhibiting Wnt5a signalling in vascular smooth muscle cells. Nat Commun 3: 1077.
89. Wong WT, Tian XY, Xu AM, Yu J, Lau CW, Hoo RLC, et al. (2011). Adiponectin is required for PPAR gamma-mediated improvement of endothelial function in diabetic mice. Cell Metab 14: 104-115.
90. Xu HE, Lambert MH, Montana VG, Parks DJ, Blanchard SG, Brown PJ, et al. (1999). Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol Cell 3: 397-403.
91. Yuen CY, Wong WT, Tian XY, Wong SL, Lau CW, Yu J, et al. (2011). Telmisartan inhibits vasoconstriction via PPARγ-dependent expression and activation of endothelial nitric oxide synthase. Cardiovasc Res 90: 122-129.
92. Zadelaar AS, Boesten LS, Jukema JW, van Vlijmen BJ, Kooistra T, Emeis JJ, et al. (2006). Dual PPARalpha/gamma agonist tesaglitazar reduces atherosclerosis in insulin-resistant and hypercholesterolemic ApoE∗3Leiden mice. Arterioscler Thromb Vasc Biol 26: 2560-2566.
93. Zarzuelo MJ, Jimenez R, Galindo P, Sanchez M, Nieto A, Romero M, et al. (2011). Antihypertensive effects of peroxisome proliferator-activated receptor-β activation in spontaneously hypertensive rats. Hypertension 58: 733-743.
94. Zarzuelo MJ, Gomez-Guzman M, Jimenez R, Quintela AM, Romero M, Sanchez M, et al. (2013). Effects of peroxisome proliferator-activated receptor-β activation in endothelin-dependent hypertension. Cardiovasc Res 99: 622-631.
95. Zhang HF, Wang L, Yuan HJ, Ma YH, Wang YF, Hu ZY, et al. (2013). PPAR-γ agonist pioglitazone prevents apoptosis of endothelial progenitor cells from rat bone marrow. Cell Biol Int 37: 430-435.
96. Zhou L, Tang YP, Gao L, Fan XS, Liu CM, Wu DK, (2009). Separation, characterization and dose-effect relationship of the PPARgamma-activating bio-active constituents in the Chinese herb formulation 'San-Ao decoction. Molecules 14: 3942-3951.
97. Zuckerman SH, Kauffman RF, Evans GF, (2002). Peroxisome proliferator-activated receptor alpha, gamma coagonist LY465608 inhibits macrophage activation and atherosclerosis in apolipoprotein E knockout mice. Lipids 37: 487-494.